Mike Hennessy Jr. is the Chairman and CEO of 

Mike Hennessy Jr.

High Angle Shot of a Working Desk of an Successful Person in Office with Cityscape Window View. | Image credit: © Gorodenkoff - stock.adobe.com

Pharmaceutical manufacturing is entering a phase defined less by singular breakthroughs and more by systems-level maturity. Across development, manufacturing, quality, and outsourcing, the industry is being asked to scale complexity without sacrificing control, whether that means adapting to new modalities, tightening regulatory timelines, or managing an increasingly outsourced supply chain. The July/August 2026 issue’s contributors offer a snapshot of what that maturity looks like in practice.

Our cover story examines downstream purification in biologics, where resilience and adaptability are becoming as important as throughput itself; operations must be built to evolve alongside the industry, not just keep pace with it. That same tension between complexity and consistency runs through our development feature on personalized therapies, where raw-material variability remains one of the toughest obstacles to reliable CAR-T and cell therapy manufacturing. Strategies like batch qualification, robust data systems, and automation are moving beyond efficiency plays and becoming prerequisites for reproducibility at the patient level.

On the automation side, contract research organizations are confronting the limits of spreadsheet-driven operations. As experimentation scales, so does the cost of manual processes, not just in time, but in compliance risk, traceability, and auditability. It’s a reminder that digitization in contract research is becoming table stakes.

This issue’s regulatory feature turns to the shifting biosimilar landscape, where faster approval pathways are reshaping market access, but, as the author notes, faster doesn’t necessarily mean easier for development teams navigating the new requirements.

Finally, our outsourcing piece makes a case that documentation reliability across contract organizations can’t be an afterthought bolted on before an audit. It must be engineered into quality systems from the start.

Taken together, these articles reflect an industry maturing under pressure to be more personalized, more outsourced, more automated, and more scrutinized than ever. Building the technical, regulatory, and organizational systems that can hold up under that pressure is the throughline.

Articles

Pharmaceutical manufacturing is shifting from isolated innovations to systems-level maturity across development, manufacturing, quality, and outsourcing. Biologics downstream purification is prioritizing resilience and adaptability alongside throughput to support evolving modality demands. Personalized therapies, particularly CAR-T and cell therapies, remain constrained by raw-material variability, driving adoption of batch qualification, robust data architectures, and automation to enable patient-level reproducibility. CROs are moving beyond spreadsheets as scale amplifies compliance, traceability, and audit risk. Meanwhile, accelerated biosimilar pathways alter access dynamics without simplifying development, and documentation reliability must be designed into partner quality systems from inception.

Across development, manufacturing, quality, and outsourcing, the pharma industry is being asked to scale complexity without sacrificing control. 

Scaling Complexity Without Losing Control

The issues that have defined pharmaceutical development and manufacturing for years— compliance burden, cost pressure, analytical complexity, and patient access—are converging in new ways. 

June 2026 issue reflects that convergence with unusual clarity.

The cover story sets an expansive frame. Partha Anbil makes the case that hybrid cloud architecture is no longer an IT consideration but a strategic imperative for life sciences organizations. He argues that as drug development pipelines grow more data-intensive and regulatory environments more demanding, the ability to balance public cloud scalability with private infrastructure control becomes a competitive differentiator. The operational and compliance dimensions of that balance are ones the industry is only beginning to navigate in earnest.

On the biologics front, 2 articles examine the formulation and manufacturing challenges that continue to test developers. Cynthia Challener's deep dive into biosimilar formulation puts into sharp relief the layered complexity facing development teams: demonstrating analytical comparability, engineering stable high-concentration and buffer-free formulations for self-administration, and doing all of it within compressed timelines while navigating patent protections on excipients. Meanwhile, Cheryl Barton reports on European biotechs advancing decentralized next-generation manufacturing platforms for cell and gene therapies (CGTs), an encouraging signal that the access bottlenecks long associated with CGTs may be yielding to manufacturing innovation.

Rounding out this issue's technical content is a peer-reviewed study from Pramote Cholayudth that addresses a precise but consequential problem in capsule filling operations: the statistical bias introduced when net fill weight is computed by subtracting a fixed average shell weight from gross weight.

Taken together, this issue captures an industry in productive tension, between cloud agility and regulatory control, between biosimilar ambition and formulation constraint, and between manufacturing scale and patient access. That tension, thoughtfully managed, is where pharmaceutical progress happens.

Pharmaceutical development and manufacturing challenges—compliance burden, cost pressure, analytical complexity, and access—are increasingly interdependent. Hybrid cloud architectures are positioned as strategic infrastructure, enabling scalable analytics while maintaining regulatory-grade control. Biologics work highlights biosimilar formulation hurdles, including comparability expectations, high-concentration/buffer-free stability for self-administration, compressed timelines, and excipient patent constraints. In cell and gene therapy, decentralized European manufacturing platforms suggest a pathway to alleviate chronic access bottlenecks. A technical study adds rigor by quantifying bias in capsule net fill calculations.

PharmTech Europe's June 2026 issue reflects the convergence of compliance burden, cost pressure, analytical complexity, and patient access.

Precision, Scale, and Compliance

The pharmaceutical industry continues to evolve at the intersection of digital transformation, regulatory rigor, and patient-centered innovation. Across development and manufacturing, companies are balancing the need for speed and efficiency with growing expectations around data integrity, product quality, and operational resilience. The articles in this issue reflect an industry increasingly defined by smarter systems, stronger analytics, and more adaptive manufacturing strategies.

“Hybrid Cloud Architecture in Pharmaceutical Development and Manufacturing,”

 highlights how digital infrastructure is becoming a strategic differentiator. As organizations manage growing volumes of development and manufacturing data, hybrid cloud models are enabling companies to accelerate workflows while maintaining the control and compliance required in highly regulated environments. The convergence of scalability, cybersecurity, and regulatory oversight is rapidly reshaping how life sciences organizations approach modernization.

At the manufacturing level, process understanding and statistical rigor remain essential. This issue’s peer-reviewed article examining T- and F-test evaluation for biased net fill weight calculations demonstrates the industry’s continued emphasis on scientifically justified, GMP-aligned approaches to in-process control. As manufacturing operations become increasingly data-driven, the ability to validate and defend analytical methodologies is more important than ever.

In development, biosimilars continue to present both opportunity and complexity. Our feature on biosimilar formulation explores the growing demand for patient-centric delivery approaches, including high-concentration and self-administered products. Developers must now navigate analytical comparability requirements, evolving regulatory expectations, and formulation challenges—all within compressed development timelines.

Quality and compliance also remain central themes throughout the industry. In 

“Risk-Based Lifecycle Management of Master Production and Control Records,”

 Dennis Cantellops examines how companies can strengthen data integrity and inspection readiness through structured governance of production records. As regulators place increasing focus on documentation practices and electronic systems, lifecycle management strategies are becoming critical to maintaining compliance and operational continuity.

 column addresses the complexities of investigating patient complaints involving prefilled syringes and combination products. As drug-device combinations become more common, manufacturers face heightened expectations for complaint handling, root-cause analysis, and patient safety oversight.

Together, these articles underscore a broader industry trend: success in modern pharma manufacturing depends not only on scientific advancement, but also on the ability to integrate digital capability, quality systems, and regulatory preparedness into every stage of the product lifecycle.

Mike Hennesy, Jr.
President and CEO
MJH Life Sciences

Pharma operations are increasingly shaped by digital transformation, heightened regulatory scrutiny, and patient-centered product design. Hybrid cloud architectures are emerging as strategic infrastructure for scaling development and manufacturing data while preserving compliance, cybersecurity, and control. Manufacturing science continues to demand statistically defensible, GMP-aligned methods, exemplified by rigorous evaluation of biased net fill weight calculations. Biosimilar formulation programs are intensifying around high-concentration, self-administered delivery amid tight timelines and comparability expectations. Strengthened governance of production records and robust investigation of combination-product complaints remain pivotal for data integrity and inspection readiness.

Driving Resilience Through Digital Innovation

The bio/pharmaceutical industry is navigating one of the most consequential periods of transformation in history. From the regulatory frameworks that govern drug approval to the laboratory benches where tomorrow’s cancer therapies are being born, change is happening at every level of the development and manufacturing continuum. This issue of 

 reflects that breadth, bringing together perspectives from scientists, engineers, regulatory strategists, and industry veterans to chart where the field is headed.

Nowhere is this transformation more visible than in the growing role of digital technology in regulatory oversight. As our cover story explores, global regulators are embedding artificial intelligence and digital tools into facility reviews and product evaluation processes. For manufacturers operating in GMP environments, and for sponsors submitting new drug applications, this shift demands a comparable evolution in how data are generated, managed, and presented. The companion piece on FDA’s digital-by-default oversight model goes further, offering a detailed operational roadmap for aligning chemistry, manufacturing, and controls and quality management systems with the agency’s increasingly data-centric expectations.

On the science side, this issue captures an extraordinary moment in oncology. The emergence of chimeric antigen receptor T-cell therapies, antibody-drug conjugates, messenger RNA-based cancer vaccines, and oncolytic virus platforms represents not merely incremental progress but a fundamental reimagining of how cancer is treated. Targets once considered undruggable are yielding to new modalities.

Behind every therapeutic advance, however, lies the unglamorous but indispensable work of manufacturing. Our peer-reviewed feature on Type III rouge remediation offers a timely example: a practical, cost-effective method for addressing a persistent challenge in stainless-steel water systems and equipment that reduces downtime and operator risk through smarter chemistry rather than disruptive mechanical intervention.

Two additional threads run through this issue: sustainability and analytical innovation. Drug manufacturers are making meaningful strides in reducing environmental impact without compromising quality, while advances in small-volume dissolution testing are ensuring that low-dose and combination drug-device products receive the rigorous performance evaluation they require.

Together, these articles paint a picture of an industry under pressure to move faster, operate smarter, and innovate more broadly than ever before while rising to meet that challenge.

Mike Hennessy Jr is Chairman and CEO of MJH Life Sciences®.

Digitalization is reshaping biopharma across development, regulatory oversight, and manufacturing. Global authorities are integrating AI and data-driven tools into inspections and product evaluation, raising expectations for how GMP data are captured, governed, and submitted. In oncology, next-generation modalities—including CAR T cells, ADCs, mRNA cancer vaccines, and oncolytic viruses—are expanding therapeutic reach, including against historically “undruggable” targets. Manufacturing execution remains pivotal, with practical chemical approaches to Type III rouge remediation reducing downtime and operator risk. Sustainability initiatives and improved small-volume dissolution testing further strengthen product performance evaluation.

This issue of PharmTech brings together perspectives from scientists, engineers, regulatory strategists, and industry veterans to chart where the field is headed.

Innovation Reshaping Pharma’s Future

The bio/pharmaceutical industry is operating at a remarkable intersection of scientific discovery, regulatory evolution, and manufacturing sophistication. This issue of 

 captures that convergence across its full scope, from the regulatory frameworks reshaping how drugs are approved and monitored, to the emerging therapies redefining what is therapeutically possible, to the operational realities of producing complex medicines safely and sustainably.

Digital transformation continues to set the pace for regulatory affairs. Our cover story examines how regulators are integrating artificial intelligence and advanced digital tools into facility inspections and product reviews, creating new expectations for pharmaceutical companies navigating the approval process and for manufacturers upholding good manufacturing practice standards. The quality theme continues in our manufacturing article, which examines how incorporating sustainability into the early development phase creates greener pharmaceutical manufacturing.

Europe, meanwhile, is charting its own course. This issue spotlights a compelling frontier in immunology: proteasome-targeting therapies, which hold promise for eliminating disease-causing proteins across a wide range of conditions. Combined with the latest European Regulatory Watch, these features reflect the increasingly global and scientifically ambitious character of drug development today.

On the development front, the oncology pipeline remains one of the most dynamic in the industry. Chimeric antigen receptor T-cell (CAR-T) and other cell-based immunotherapies, antibody-drug conjugates, messenger RNA cancer vaccines, and oncolytic virus platforms are advancing through the clinic, collectively targeting disease pathways that were, until recently, considered beyond reach. The breadth of these modalities signals a new era of precision oncology.

Translating these advances into reliable, scalable products demands manufacturing excellence. Our peer-reviewed feature addresses a persistent challenge in pharmaceutical water systems (type III magnetite rouge), presenting a smarter remediation approach that cuts downtime, reduces operator risk, and preserves equipment integrity. Ensuring the purity and sterility of those products is equally critical, and our analytics feature explores the evolving landscape of analytical technologies for aseptic processing, from current best practices to emerging innovations on the horizon.

Rounding out the issue, our outsourcing coverage examines how CDMOs are adapting their formulation services to meet the demands of patient-centric therapies and rare disease treatments, a reflection of how deeply personalized medicine is reshaping the contract services landscape.

Across every section, a single theme emerges: an industry building the future with rigor, creativity, and purpose.

Pharma's Digital, Scientific, and Manufacturing Evolution

 has been the voice for practical, real-world strategy. We make complex breakthroughs professionally applicable, and we fundamentally drive advanced development and manufacturing every day.

Today, we’re taking our brand to the next level so we can strengthen our commitment to scientists, innovators, and C-suite leaders who trust us for science-driven insights for faster and smarter manufacturing of safe, effective, successful therapies.

We earned our place as the market leader by creating uniquely expert content and engaging media platforms. Through 2025, we developed a bold, new look and content strategy. The design is incredible and we’re excited for you to experience it.

Our content authority comes from alignment with top experts across the field. By staying united with key opinion leaders in pharma, we can deliver impartial and objective insights. Our new media strategy elevates these stars, giving them the spotlight they deserve.

For more than 25 years, the official name has been 

. You do, too. Everyone does. Why? It’s precise. Gets right to the point. It’s picture-perfect for our approach to the industry.

Call us humble. We earned #1, and we focus on excellence. But this industry is defined by competition. So, we’re putting on the gloves as the comprehensive leader in engagement with key decision-makers in pharma and biopharma. Reach, quality, versatility—always.

Mike Hennessy Jr
President and CEO
MJH Life Sciences